Results 241 to 250 of about 18,913,418 (345)

Correction: Structures of human protein tyrosine phosphatase variants reveal targetable allosteric sites. [PDF]

J Biol Chem
Perdikari A, Woods VA, Ebrahim A, Lawler K, Bounds R, Shah DS, Singh NI, Mehlman TS, Riley BT, Sharma S, Morris JW, Keogh JM, Henning E, Smith M, Farooqi IS, Keedy DA.   +15 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Beta-lactam antibiotics have immunomodulatory effects in vitro, including changes consistent with sepsis-induced immunosuppression. [PDF]

Crit Care
Snow TAC, Charoenpong S, Kim H, Carthigesan K, Gallagher L, Elkhodair S, Avraham R, Das A, Singer M, Brealey D, Arulkumaran N, University College London Hospitals Critical Care Research Team.   +11 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Annual report of the Correctional Investigator.

, 1987

core  

Coordinated clinical trial networks in nephrology: strengthening research infrastructure and improving trial delivery. [PDF]

Clin Kidney J
de Borst MH, Adema AY, Balak J, Heerspink HJL, Schoutteten M, Hoogeveen EK, Hoorn EJ, Leenders N, Meijvis SCA, Ocak G, Rotmans JI, Waanders F, NEFRO-NL Collaborators, Duivenvoorden R, Vogt L, NEFRO-NL Collaborators .   +15 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa. [PDF]

J Inherit Metab Dis
Mitchell JJ, Abdenur JE, de Boer F, Boyer M, Breilyn MS, Couce ML, De Leon DD, Derks TG, El-Gharbawy A, Haijer-Schreuder AB, Loechner K, Longo N, Lund AM, Olmos MAM, McCandless SE, de Oliveira BM, Mount M, Muschol N, Pytlak K, Radhakrishnan K, Riba-Wolman R, Rodriguez-Buritica DF, La Rosa A, Rossi A, Saavedra H, Santer R, Shayota B, Smit GPA, Moura De Souza CF, van der Klauw MM, Weinstein DA, Wolfsdorf JI, Blake A, Grimm AA, Mitragotri D, Rahman S, Turner-Bowker DM, Collis R.   +37 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Evaluating Financial Literacy Among Medical Students: A Cross-Sectional Study. [PDF]

PRiMER
Daybell I, Hohl K, Bracamonte J, Sharma U.   +3 more
europepmc   +1 more source